Previous 10 | Next 10 |
2024-05-17 08:39:32 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus stock falls 9% amid Q1 report, cost-cutting measures Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints ...
Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of ...
2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...
2024-05-08 16:15:29 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...
2024-05-08 07:22:41 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million Enrollment to be completed mid-May in the Phase 3 TrustTSC trial ...
2024-05-07 14:08:21 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Al...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capit...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...